130 related articles for article (PubMed ID: 10620064)
1. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Derenne S; Amiot M; Barillé S; Collette M; Robillard N; Berthaud P; Harousseau JL; Bataille R
J Bone Miner Res; 1999 Dec; 14(12):2048-56. PubMed ID: 10620064
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect.
Corso A; Ferretti E; Lunghi M; Zappasodi P; Mangiacavalli S; De Amici M; Rusconi C; Varettoni M; Lazzarino M
Cancer; 2005 Jul; 104(1):118-25. PubMed ID: 15895374
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinases-1 and -2, and tissue inhibitor of metalloproteinase-2 production is abnormal in bone marrow stromal cells of multiple myeloma patients.
Zdzisińska B; Walter-Croneck A; Kandefer-Szerszeń M
Leuk Res; 2008 Nov; 32(11):1763-9. PubMed ID: 18472160
[TBL] [Abstract][Full Text] [Related]
4. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells.
Barillé S; Collette M; Thabard W; Bleunven C; Bataille R; Amiot M
Cytokine; 2000 Sep; 12(9):1426-9. PubMed ID: 10976008
[TBL] [Abstract][Full Text] [Related]
5. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate treatment inhibits the growth of prostate cancer cells.
Lee MV; Fong EM; Singer FR; Guenette RS
Cancer Res; 2001 Mar; 61(6):2602-8. PubMed ID: 11289137
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone.
Cheng YY; Huang L; Lee KM; Xu JK; Zheng MH; Kumta SM
Calcif Tissue Int; 2004 Jul; 75(1):71-7. PubMed ID: 15037971
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
[TBL] [Abstract][Full Text] [Related]
10. Production of metalloproteinase-7 (matrilysin) by human myeloma cells and its potential involvement in metalloproteinase-2 activation.
Barillé S; Bataille R; Rapp MJ; Harousseau JL; Amiot M
J Immunol; 1999 Nov; 163(10):5723-8. PubMed ID: 10553104
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase and cytokine production by bone marrow adherent cells from multiple myeloma patients.
Zdzisińska B; Walter-Croneck A; Dmoszyńska A; Kandefer-Szerszeń M
Arch Immunol Ther Exp (Warsz); 2006; 54(4):289-96. PubMed ID: 16868721
[TBL] [Abstract][Full Text] [Related]
12. Regulation of interleukin 6 in multiple myeloma and bone marrow stromal cells.
Chauhan D; Uchiyama H; Urashima M; Yamamoto K; Anderson KC
Stem Cells; 1995 Aug; 13 Suppl 2():35-9. PubMed ID: 8520509
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
14. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
Tassone P; Galea E; Forciniti S; Tagliaferri P; Venuta S
Int J Oncol; 2002 Oct; 21(4):867-73. PubMed ID: 12239628
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate induces apoptosis in cells from fibro-cellular membrane of unicameral bone cyst (UBC).
Yu J; Chang SS; Suratwala S; Chung WS; Abdelmessieh P; Lee HJ; Yang J; Lee FY
J Orthop Res; 2005 Sep; 23(5):1004-12. PubMed ID: 15921873
[TBL] [Abstract][Full Text] [Related]
16. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells.
Dumon JC; Journé F; Kheddoumi N; Lagneaux L; Body JJ
Eur Urol; 2004 Apr; 45(4):521-8; discussion 528-9. PubMed ID: 15041119
[TBL] [Abstract][Full Text] [Related]
17. Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
Koizumi M; Nakaseko C; Ohwada C; Takeuchi M; Ozawa S; Shimizu N; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2007 Nov; 79(5):382-91. PubMed ID: 17903213
[TBL] [Abstract][Full Text] [Related]
18. Modulation of osteoclast-activating factor activity of multiple myeloma bone marrow cells by different interleukin-1 inhibitors.
Torcia M; Lucibello M; Vannier E; Fabiani S; Miliani A; Guidi G; Spada O; Dower SK; Sims JE; Shaw AR; Dinarello CA; Garaci E; Cozzolino F
Exp Hematol; 1996 Jul; 24(8):868-74. PubMed ID: 8690044
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Aparicio A; Gardner A; Tu Y; Savage A; Berenson J; Lichtenstein A
Leukemia; 1998 Feb; 12(2):220-9. PubMed ID: 9519785
[TBL] [Abstract][Full Text] [Related]
20. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
